Published in Cancer Res on September 01, 2006
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging (2008) 1.17
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging (2007) 1.10
Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells. J Nucl Med (2010) 1.00
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck (2008) 0.96
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med (2009) 0.93
The role of nucleoside/nucleotide transport and metabolism in the uptake and retention of 3'-fluoro-3'-deoxythymidine in human B-lymphoblast cells. Nucl Med Biol (2011) 0.92
Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res (2008) 0.87
Hedgehog signaling sensitizes glioma stem cells to endogenous nano-irradiation. Oncotarget (2014) 0.84
The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells. Nucl Med Biol (2012) 0.83
Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. Am J Nucl Med Mol Imaging (2015) 0.83
In vitro analysis of transport and metabolism of 4'-thiothymidine in human tumor cells. Nucl Med Biol (2014) 0.82
Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography. PLoS One (2013) 0.82
Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. Br J Cancer (2014) 0.81
The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer Metastasis Rev (2008) 0.81
Development of radiotracers for oncology--the interface with pharmacology. Br J Pharmacol (2011) 0.81
[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941. Mol Cancer Ther (2013) 0.81
Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models. Eur J Nucl Med Mol Imaging (2011) 0.80
Levels of human equilibrative nucleoside transporter-1 are higher in proliferating regions of A549 tumor cells grown as tumor xenografts in vivo. Nucl Med Biol (2012) 0.78
The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture. Br J Radiol (2010) 0.78
A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine. Mol Imaging Biol (2011) 0.75
Evaluation of (18)F-fluorothymidine positron emission tomography ([(18)F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer. EJNMMI Res (2016) 0.75
FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study. EJNMMI Res (2017) 0.75
Response Monitoring with [(18)F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases. Mol Imaging Biol (2016) 0.75
Murine leukemia induced by retroviral gene marking. Science (2002) 3.59
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res (2003) 2.46
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 2.35
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med (2008) 2.27
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Inhalation of nitric oxide prevents ischemic brain damage in experimental stroke by selective dilatation of collateral arterioles. Circ Res (2011) 1.91
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst (2006) 1.83
Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum (2009) 1.77
Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res (2011) 1.64
Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements. J Nucl Med (2010) 1.55
The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res (2009) 1.47
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res (2007) 1.45
Correlation between automated writing movements and striatal dopaminergic innervation in patients with Wilson's disease. J Neurol (2002) 1.43
Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res (2005) 1.43
Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res (2005) 1.42
Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther (2002) 1.39
The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging (2004) 1.38
[18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol (2003) 1.36
Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A (2009) 1.34
Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther (2006) 1.33
A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res (2009) 1.32
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res (2005) 1.24
Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One (2011) 1.24
Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage (2009) 1.23
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Cancer Res (2006) 1.19
The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res (2002) 1.16
Permanent middle cerebral artery occlusion in sheep: a novel large animal model of focal cerebral ischemia. J Cereb Blood Flow Metab (2008) 1.12
Summary report of the First International Workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany. Mol Imaging Biol (2013) 1.10
Definition of primary and secondary glioblastoma--letter. Clin Cancer Res (2014) 1.09
Executive deficits are related to the inferior frontal junction in early dementia. Brain (2011) 1.09
Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry (2009) 1.08
PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med (2013) 1.08
Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther (2004) 1.08
Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther (2007) 1.08
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res (2009) 1.08
Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging (2010) 1.05
Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem (2008) 1.05
Internet-based parent management training: a randomized controlled study. Behav Res Ther (2012) 1.04
Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI. Psychiatry Res (2012) 1.04
A randomized controlled effectiveness trial of parent management training with varying degrees of therapist support. Behav Ther (2010) 1.02
Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res (2003) 1.01
An in vivo multimodal imaging study using MRI and PET of stem cell transplantation after myocardial infarction in rats. Mol Imaging Biol (2008) 1.01
[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res (2011) 1.00
PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol (2013) 0.99
Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med (2009) 0.99
Glucose metabolism measured by [¹⁸F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Transl Oncol (2011) 0.98
Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res (2009) 0.98
Exploitation of the folate receptor in the management of cancer and inflammatory disease. Vitam Horm (2008) 0.98
Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther (2008) 0.96
Executive and behavioral deficits share common neural substrates in frontotemporal lobar degeneration - a pilot FDG-PET study. Psychiatry Res (2010) 0.96
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res (2013) 0.96
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol (2008) 0.95
18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med (2013) 0.95
Systemic chemotherapy for patients with bladder cancer--current controversies and future directions. Cancer Treat Rev (2004) 0.94
Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res (2005) 0.93
Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res (2006) 0.93
Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. Blood (2009) 0.93
Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET. PLoS One (2013) 0.93
Different mechanisms for changes in glucose uptake of the right and left ventricular myocardium in pulmonary hypertension. J Nucl Med (2005) 0.92
Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. Cancer Res (2003) 0.92
Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res (2013) 0.92
Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging. Cancer Res (2006) 0.92
The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res (2004) 0.91
Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot (2003) 0.90
Synthesis and in vitro evaluation of [18F]fluoroethyl triazole labelled [Tyr3]octreotate analogues using click chemistry. Bioorg Med Chem Lett (2011) 0.90
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin Cancer Res (2002) 0.90
Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography. Clin Cancer Res (2012) 0.90
Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res (2004) 0.90
Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up. J Neurol (2008) 0.89
Visualising androgen receptor activity in male and female mice. PLoS One (2013) 0.89
Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies. Phys Med Biol (2010) 0.89
[11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res (2009) 0.89
Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [(18)F]ICMT-11. Eur J Cancer (2012) 0.89
Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany. Mol Imaging Biol (2014) 0.88
Magnetic nanoparticles as contrast agents in the diagnosis and treatment of cancer. Chem Soc Rev (2013) 0.87
Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res (2009) 0.87
Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol (2003) 0.87
Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res (2008) 0.87
Dissociating behavioral disorders in early dementia-An FDG-PET study. Psychiatry Res (2011) 0.87
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res (2003) 0.87
Quantification of receptor-ligand binding with [¹⁸F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging (2011) 0.87
A phantom for diffusion-weighted MRI (DW-MRI). J Magn Reson Imaging (2013) 0.87
Dissociating memory networks in early Alzheimer's disease and frontotemporal lobar degeneration - a combined study of hypometabolism and atrophy. PLoS One (2013) 0.87
Neural correlates of the DemTect in Alzheimer's disease and frontotemporal lobar degeneration - A combined MRI & FDG-PET study. Neuroimage Clin (2013) 0.86
Bioorthogonal chemistry for pre-targeted molecular imaging--progress and prospects. Org Biomol Chem (2013) 0.86
Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. Childs Nerv Syst (2014) 0.85
Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer. Mol Imaging Biol (2012) 0.85